Laboratory Corporation of America Holdings ($LH) Stock Forecast: Down 1.0% Today

What is Laboratory Corporation of America Holdings?

Labcorp Holdings (LH) has observed a bearish movement in the market today.

Why is Laboratory Corporation of America Holdings going down?

LH stock is down 1.0% on Feb 2, 2026 15:45

• Labcorp Holdings recently extended its receivables facility and included a $125 million accordion feature, enhancing financial flexibility. However, this positive development did not significantly influence market activity.
• Thrivent Financial for Lutherans raised its stake in Labcorp Holdings, indicating strong investor confidence, though the stock continued to trend bearishly.
• Speculation about Labcorp Holdings being undervalued, with suggestions of a fair value of $300.06 per share, could be influencing the bearish movement as investors exercise caution.
• Guardant Health's FDA approval for its liquid biopsy for colorectal cancer may have redirected some attention and investments from Labcorp Holdings, resulting in a negative impact on its market performance.

LH Price Chart

LH Technical Analysis

LH News

Thermo Fisher Scientific’s venture arm brings Massey onboard

Thermo Fisher Scientific's corporate venture arm has hired Carson Massey as an associate director. Massey previously spent five years at LabCorp Venture Fund, where he focused on corporate development within the biotech equipment sector. He will join Thermo Fisher Scientific’s strategic capital team under Bhooshi De Silva, contributing to the firm's startup investments, which have recently included miDiagnostics and CytoReason.

https://globalventuring.com/corporate/people/thermo-fisher-scientific-brings-massey-onboard/

New myeloma blood test offers alternative to painful bone marrow biopsies

Quest Diagnostics has launched a new ultrasensitive blood test, Quest Flow Cytometry MRD for Myeloma, which aims to improve the detection and monitoring of measurable residual disease (MRD) in multiple myeloma patients. This test offers sensitivity comparable to next-generation sequencing but at a lower cost and uses non-invasive blood samples, providing an alternative to painful bone marrow biopsies. The new test also boasts a five-day specimen stability, making it more accessible for nationwide testing, and can be used without a pre-treatment baseline aspirate.

https://www.stocktitan.net/news/DGX/quest-diagnostics-launches-novel-flow-cytometry-mrd-blood-test-for-v9w8imthp0d4.html

A Look At Labcorp Holdings (LH) Valuation After Receivables Facility Extension And Added Accordion Feature

Labcorp Holdings (LH) recently extended its receivables facility to January 26, 2029, and added a $125 million accordion feature, providing financial flexibility. Despite a steady year-to-date share price return of 7.9% and a 9.9% one-year total shareholder return, the stock trades at a 52.7% discount to one intrinsic estimate, suggesting potential undervaluation. The most popular narrative suggests a fair value of $300.06 per share, driven by anticipated growth from innovative tests in various medical fields.

https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/a-look-at-labcorp-holdings-lh-valuation-after-receivables-fa

Labcorp Holdings Inc. $LH Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its stake in Labcorp Holdings Inc. ($LH) by 8.8% in Q3, bringing its total to 563,006 shares valued at $161.6 million. Institutional investors collectively own 95.94% of Labcorp stock, reflecting strong investor confidence. Analysts maintain a "Moderate Buy" rating with an average price target of $299.77, and Labcorp recently declared a quarterly dividend of $0.72 per share, yielding about 1.1%.

https://www.marketbeat.com/instant-alerts/filing-labcorp-holdings-inc-lh-shares-bought-by-thrivent-financial-for-lutherans-2026-02-01/

Should FDA’s New Colorectal Cancer CDx Approval Reshape Guardant Health’s (GH) Liquid Biopsy Investment Case?

Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy for BRAF V600E-mutant metastatic colorectal cancer, strengthening its position in non-invasive genomic profiling. This approval, alongside a new Merck collaboration, reinforces the clinical relevance and utilization of Guardant's technology, but the company remains unprofitable with a high valuation. Investors should critically assess execution on 2025 guidance and the translation of companion diagnostic wins into meaningful, reimbursed volume.

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/should-fdas-new-colorectal-cancer-cdx-approval-reshape-guard

Trending Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.0% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.0% Today

Interactive Brokers Group, Inc. ($IBKR) Stock Forecast: Up 3.8% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 5.4% Today

Carvana Co ($CVNA) Stock Forecast: Up 5.3% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 7.5% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 5.1% Today

IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Down 1.7% Today

Silver ($XAG) Commodity Forecast: Down 5.4% Today

Laboratory Corporation of America Holdings Price History

02.01.2026 - LH Stock was down 1.0%

• Labcorp Holdings recently extended its receivables facility and included a $125 million accordion feature, enhancing financial flexibility. However, this positive development did not significantly influence market activity.
• Thrivent Financial for Lutherans raised its stake in Labcorp Holdings, indicating strong investor confidence, though the stock continued to trend bearishly.
• Speculation about Labcorp Holdings being undervalued, with suggestions of a fair value of $300.06 per share, could be influencing the bearish movement as investors exercise caution.
• Guardant Health's FDA approval for its liquid biopsy for colorectal cancer may have redirected some attention and investments from Labcorp Holdings, resulting in a negative impact on its market performance.

14.02.2024 - LH Stock was down 2.9%

• The appointment of Bryan Riggsbee to CareDx's Board of Directors brings financial expertise and experience from other companies, potentially signaling a strategic advantage for CareDx over LabCorp.
• The insider selling of shares by Mark Schroeder, EVP and President Diagnostics & COO of LabCorp, may have raised concerns among investors about the company's future performance.
• The research report on the Europe Medical Diagnostics Market, including competitive analysis of LabCorp, Quest Diagnostics, and others, could have highlighted potential challenges or increased competition for LabCorp, impacting its stock performance negatively.
• Overall, these factors combined might have contributed to the bearish movement of LabCorp's stock today.

27.05.2023 - LH Stock was down 1.0%

• LH had a strong bearish movement today.
• The article suggests that the predictability of LH's cash flows is less visible, which may have contributed to the market movement.
• The article also mentions that LH's return on capital employed has lagged behind the required rate of return in the last two periods, which could be another factor affecting the stock's performance.

25.03.2024 - LH Stock was down 3.7%

• Labcorp reported its first-quarter results, showing an increase in profit that missed estimates, leading to a decline in its shares despite exceeding earnings expectations.
• The company revised its adjusted earnings and revenue growth guidance range for the fiscal year 2024, potentially disappointing investors.
• Despite a strong first-quarter performance, Labcorp faced high market expectations, resulting in a bearish trend in its stock price.
• The adjustment of the full-year guidance range and missing analyst estimates likely contributed to the negative market sentiment towards Labcorp today.

29.03.2024 - LH Stock was up 2.9%

• Received FDA approval for the nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic for Pfizer's gene therapy to treat Hemophilia B patients.
• Approval signifies a significant advancement in precision medicine and gene therapy, underlining Labcorp's leadership in the field.
• Q1 revenue surpassed forecasts, showing a 4.6% increase driven by organic growth and acquisitions, boosting investor confidence in the company's future prospects.
• Market responded positively to the developments, with investors likely optimistic about Labcorp's sustained success in precision medicine and gene therapy.

15.01.2024 - LH Stock was down 1.1%

• The recent decline in the stock of LH could be attributed to the following factors:
• 1. Lower-than-expected earnings: Labcorp's Q4 earnings were notably lower compared to the same period last year, resulting in a negative EPS. This decline in profitability may have affected investor sentiment and contributed to the bearish market movement.
• 2. Disappointing revenue growth: Although Labcorp reported higher revenue for the fourth quarter and full year compared to the previous year, the growth rate fell short of expectations. This slower revenue growth may have raised concerns among investors about the company's ability to sustain its performance in the future.
• 3. Uncertainty in future earnings: While Labcorp provided guidance for 2024 profit that exceeded Wall Street expectations, the lack of clarity in the earnings forecast could have influenced the bearish market movement. Investors may be cautious about potential challenges or uncertainties that could impact Labcorp's profitability in the coming years.
• 4. Overall market sentiment: The broader market conditions and investor sentiment towards the life sciences sector could have also played a role in Labcorp's stock decline. Factors such as macroeconomic trends, industry competition, and regulatory developments can impact investor confidence and contribute to market fluctuations.

03.06.2023 - LH Stock was down 13.0%

• The bearish movement in LH's stock today could be attributed to the following factors:
• 1. Anticipation of second-quarter financial results: Investors may have been cautious ahead of Labcorp's upcoming financial results announcement. Uncertainty surrounding the company's performance could have led to selling pressure on the stock.
• 2. Market sentiment towards medical research stocks: Despite the potential for growth in the medical research industry, overall market sentiment towards this sector might have been negative today. This negative sentiment could have influenced the bearish movement in LH's stock.
• 3. Lack of positive catalysts: The absence of any specific positive news or developments related to Labcorp may have contributed to the bearish movement. Without any significant catalysts to drive the stock higher, investors may have chosen to sell their positions.
• 4. General market conditions: It's important to consider that broader market conditions and macroeconomic factors can also impact individual stock movements. If the overall market experienced a bearish trend today, it could have influenced LH's stock as well.

20.04.2024 - LH Stock was down 2.6%

• Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard retired from Labcorp's board of directors, which potentially led to investor uncertainty.
• Despite the introduction of a new first-trimester preeclampsia screening test, the market did not respond positively to this development.
• The sale of over $420k in company stock by a Labcorp executive may have sparked concerns about insider sentiment and future company performance.
• The overall bearish movement in Labcorp's stock today could be attributed to a combination of key personnel changes, new product launches, and insider selling.